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The purpose this study was to develop a psychometrically sound paper-n-pencil 
questionnaire for the measuring and diagnosing of anosognosia in Alzheimer’s disease 
(AD).  Anosognosia is defined as the lack of awareness one has towards one’s own state.  
It manifests within AD as an unawareness of symptoms the individual is experiencing.  
The initial 43-item questionnaire was administered to 67 AD patients (age: u = 72.66, SD 
= 3.40), with 41 females and 26 males.  A Cronbach’s-alpha of 0.89 was obtained 
showing the questionnaire had excellent internal reliability.   
The 43 items in the original questionnaire were reduced to 10 using the internal 
reliability analysis.  The 10-item questionnaire was administered to a new group of 83 
AD patients (age: u = 75.83, SD = 3.83), with 58 females and 25 males.  Internal 
reliability of the new questionnaire remained high with an obtained Cronbach’s-alpha of 
0.87.  Correlations between the sample population 10-item questionnaire score and the 
Mini Mental State Exam (r = -0.24, p < 0.05) and Geriatric Depression Scale (r = -0.30, 
p < 0.05) showed a low but significant correlation.  The 8-Point Clock Drawing (r = -
0.04, p > 0.05), and Zarit’s Caregiver Burden Scale (r = 0.04, p > 0.05) showed no 
correlation.  Using 19 of the patients a one-way Intraclass Coefficient (ICC) was used to 
determine inter-rater agreement (alpha = 0.63).   Twenty-one of the patients were used for 
the purpose of test-retest and resulted in a Pearson-r correlation of r = 0.70 (p < 0.000).  
Forty-three normal subjects were enrolled in the study (age: u = 73.95, SD = 
3.90) with 23 females and 20 males.  Using the normals mean + 2SD a cutoff score of 12 




Using the cutoff value there were 42 AD patients who had anosognosia which was 51% 
of the sample population. 
The questionnaire was found to be reliable though further studies would be 
needed to confirm the results by expanding the sample size and using more generalized 
inclusion criteria.  Nevertheless, the questionnaire showed little relationship to the other 
questionnaires administered during the study.  This helps to show the questionnaire is 
measuring a unique phenomenon which is not related to other standard diagnostic 
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1. LITERATURE REVIEW 
1.1 Alzheimer’s disease 
In 1901 Auguste D was a 51-year-old patient who was committed to the Frankfurt 
Asylum with what was considered to be unusual symptoms (Schneider & Dagerman, 
2004).  Alzheimer, who was a physician on staff, became fascinated with Auguste's state 
and followed her slow cognitive decline until her death 5 years later.  Alzheimer had her 
brain sent to Kraeplin's laboratory in Munich where the two examined the brain using 
new staining techniques to identify a large amount of amyloid plaques and neurofibrillary 
tangles within the brain tissue (Small & Cappai, 2006).  The same year Alzheimer 
presented both his pathological and clinical symptoms of presenile dementia noting 
Auguste’s memory loss, disorientation, hallucinations, and untimely death.  Later the 
disease was unintentionally named when Kraeplin used the term “Alzheimer’s disease” in 
a textbook he authored (Morris & Salmon, 2007). 
Alzheimer’s disease (AD)  has become the most common form of dementia, 
representing more then 60% of today’s current dementia diagnoses (Ferri, et al., 2005).  It 
is estimated that in 2000 over 4 to 4.5 million people in the United States were suffering 
from AD, and it is estimated that this number may triple or quadruple by 2050 (Kawas, 
2003).  In 2006, the worldwide estimate for the prevalence of AD was 26.6 million.  This 
number is also expected to increase in relation to the United States estimate, with 1 in 85 
persons in the world being afflicted by the disease ((Brookmeyer, Johnson, Ziegler-
Graham, & Arrighi, 2007).   
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AD has a slow onset with the disease classified into 3 stages; mild, moderate, and 
severe.  Mild AD is characterized by small changes in normal cognitive functioning such 
as the ability to remember recent events or information (Peterson, 2007).  As the disease 
progresses into the moderate stage the individual’s cognitive functions deteriorate to 
where there is a decrease in the level of independence in relation to activities of daily 
living (ADL).  The individual may also require greater assistance in performing more 
cognitively challenging tasks.  The disease will then progress into the severe stage.  
During the severe stage an individual looses the ability to function on a day-to-day basis.  
Symptoms can include inability to recognize family members, problems speaking, 
performing simple daily activities, or changes in personality or behaviors.  The 3 stage 
model is most commonly used though there have been other scales introduced in an effort 
to stage AD, such as Reisberg’s (1982) subjective 7 stage Physician-rated questionnaire 
called the Global Deterioration Scale (G.D.S.) (Table 1).    
Table 1. Global Deterioration Scale (G.D.S.) 
7 Stage of decreasing ability 
 
Stage 1: No cognitive decline 
Stage 2: Very mild cognitive decline 
Stage 3: Mild cognitive decline 
Stage 4: Moderate cognitive decline 
Stage 5: Moderately severe cognitive decline 
Stage 6: Severe cognitive decline 
Stage 7: Very severe cognitive decline 
 





 The widely accepted diagnosis criterion for probable AD is the National Institute 
(McKhann, et al., 1984).   The criteria states that dementia needs to be established by 
clinical examination and documented by cognitive tests, confirmed by 
neuropsychological testing, contain at least two areas of cognition deficit, demonstrate 
progressive worsening of symptoms, have an onset between 40 and 90 years of age, and 
an  absence of any other systematic or brain disease capable of producing dementia 
(Cummings, 2007).  
Though the previous standard has been used for over 2 decades, today it is 
common place for a PET scan to also be performed in order to differentiate between AD 
and frontotemporal dementia (FTD) (Corey-Bloom, et al., 1995).  The reasoning for a 
PET scan is that FTD will often meet the diagnostic criteria for AD (Varma, et al., 1999).  
The use of a PET scan helps to determine if there is severe hypometabolism in the 
frontotemporal area of the brain which is an identifying feature of FTD and thereby will 
rule out AD.  
As with staging, the NINCDS-ADRDA is not the only existing diagnostic criteria (Table 
2).  The International Classification of Disease, 10th revision (ICD-10) criteria includes 
the presence of dementia, insidious onset, slow deterioration of cognition, absence of 
clinical or laboratory evidence of a systematic illness or brain disease that can induce 
dementia, and the absence of a history of sudden onset of neurological signs indicative of 
focal brain injury.  The Diagnostic and Statistic Manual of Mental Disorders, 4th edition 
(DSM-IV) (APA, 1994) and Diagnostic and Statistic Manual of Mental Disorders - 
Revised, 4th edition   (DSM-IV-TR) (APA, 2000) requires a gradual onset and a  
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Table 2. Three Criteria for AD Diagnosis 
 
Cummings, J. (2004). Definitions and diagnostic criteria. In Clinical 
Diagnosis and Management of Azlheimer's Disease. 3nd Edition. Ed. S. 




Memory decline + + + 
Thinking impairment + - - 
Aphasia, apraxia, agnosia or 
disturbed executive functioning 
- + - 
Impairment of at least one non-
memory intellectual function 
+ + + 
Dementia established by 
questionnaire 
- - + 
Dementia confirmed by 
neuropsychological testing 
- - + 
ADL impairments + - - 
Social or occupational impairment - + - 
Decline from previous level + + + 
Onset between the age of 40 and 90 - - + 
Insidious onset + + - 
Slow deterioration + - + 
Continuing deterioration - + + 
Absence of clinical or laboratory 
evidence of another dementing 
disorder 
+ + + 
Absence of sudden onset + - + 
Absence of focal neurological signs + - + 
Absence of substance abuse - + - 
Deficit not limited to delirious 
period 
+ + + 
Absence of another major mental 
disorder 





continuing cognitive decline, as well as the absence of other neurological disorders, 
systematic conditions, or substance abuse sufficient to induce dementia.  Furthermore, the 
condition cannot occur during a delirium and must not be attributable to a major 
psychiatric disorder. 
Unlike the ICD-10 and DSM-IV, the NINCDS-ADRDA criteria does not rely on 
activities of daily living as a diagnostic criteria, but instead uses it as supportive 
information.  It is considered to be a weakness by some since it can cause the disease to 
be under diagnosed.  However, the NINCDS-ADRDA also has its strength since its 
criteria excludes sudden onset which is not a conventional occurrence with AD.  Also, 
unlike the DSM-IV criteria, it does not exclude patients who have substance abuse, 
depression, or schizophrenia (Cummings, 2007). 
There are 3 possible diagnostic categories for AD: definite, possible, and probable 
(Table 3).  A definite diagnosis requires the NINCDS-ADRDA criteria to be met together 
with histopathologic evidence of AD through autopsy or biopsy (Schachter & Davis, 
2000).  Probable AD requires the dementia to have onset between 40 and 90 years of age; 
that it be established by clinical examination and documented by cognitive testing; 
contain deficits in two or more areas of cognition; have a progressively worsening 
cognitive function; be devoid of any disturbance of consciousness; and the absence of 
any systematic or brain disease capable of producing a dementia syndrome.  Lastly, the 
criteria for Possible AD includes an atypical onset, presentation, or progression of a 
dementia syndrome without a known cause; the presence of a systematic or other brain 
disease capable of producing dementia, but not thought to be the cause of the dementia; 
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Table 3. Diagnosis Categories for AD  
Definite AD 
 
• Clinical criteria for probable AD. 




• Dementia established by clinical examination and documented by mental 
status questionnaire. 
• Dementia confirmed by neuropsychological testing. 
• Deficits in two or more areas of cognition. 
• Progressive worsening of memory or other cognitive functions. 
• No disturbance of consciousness. 
• Onset between 40 and 90 years of age. 





• Atypical onset, presentation, or progression of a dementia syndrome without a 
known cause.  
• Presence of a systematic or other brain disease capable of producing 
dementia, but not thought to be the cause of the dementia. 
• Gradually progressive decline in a single intellectual function in the absence 




and the gradual but progressive decline in a single intellectual function in the absence of 
any other identifiable cause (Lopez , et al., 2000).  
1.2 Pathogenesis of AD 
AD is considered to be a multifactorial disease (Blass 1993).  Associated with the 
disease are genetic and environmental factors which contribute to inflammatory 
responses in the brain and the eventual loss of neurons which ultimately lead to the 
manifestation of AD.  Most notable changes to the brain and what are believed to be the 
primary cause of AD is the presence of beta amyloid plaques and neurofibrillary tangles 
(NFT). 
Beta amyloid plaques are formed from an abnormality with the functioning of 
Amyloid precursor proteins (APP).  APP is normally found in the brain and essential to 
the brain’s development and repair.  After use APP is broken down into 37-amino-acid 
segment and is recycled to create more APP (William & Shankle, 2005).  Within the AD 
patient APP incorrectly breaks down and creates 40- and 42-amino-acid fragments.  
Called beta amyloid plaques, the fragments are not reused and begin to collect within the 
brain into protein accumulations called BA42 complexes which cause neuronal death 
(Selko, 2004). 
NFT is a cytoskeletal abnormality found in AD, though it is not unique to the 
disease itself (Terry & Katzman, 1983).  NFT appear to be created by the abnormal 
accumulation of Tau proteins which are essential to maintaining the shape and structure 
of the neuron.  Due to a mutation of a gene on chromosome 17 the Tau proteins begin to 
twist causing a neuron’s axon to become misshapen (William & Shankle, 2005).  The 
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malformed proteins block the flow of molecules from the cell body to the outer regions of 
the cell, eventually causing the death of the neuron. 
It is uncertain how the two processes are related and it is currently believed AD is 
the result of multiple factors which produce neuronal death.  Whether beta amyloid 
plaques or NFT are the initial trigger, or if they are independent occurrences causing the 
disease is still in debate (Belanger, Pearson, & Poirier, 2007). 
1.3 Risk Factors 
Age is considered the greatest risk factor for developing AD.  Ten percent of 
people over the age of 65 have AD with the risk doubling every 5 years thereafter 
(“National Institute on Aging”, 2006).  Some individuals inherit AD (Familial), though 
this occurs in less then 1% of AD cases with onset occurring before the age of 65.  
However, almost all people with Down syndrome start to show AD associated changes to 
the brain after age 40 with onset occurring in their 50s or 60s (Black, Patterson, & 
Feightner, 2001).  
Gender has not been found to be a risk factor among AD patients in the United 
States, however females in Europe and Asia have are reported to be at a higher risk then 
males (Feinberg et al., 2000).  Though the reasons are not yet fully understood, some 
investigators believe the cause may be the greater longevity of woman, difficulty in 
diagnosing males since there is a higher prevalence of cerebrovascular disease with men, 
and unexpected hormonal effects brought on by menopause and low testosterone levels 
(Belanger, et al., 2007). 
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Lower education level has been linked to an increased risk in AD (Karp et al., 
2004), while other studies failed to show an association, or an association was only 
demonstrated within subgroups. (Letenneur et al., 2000).  It is hypothesized that higher 
level of education creates improved abilities in thinking, learning, and memory which 
result in the constantly challenged brain creating a cognitive reserve.  The reserve allows 
the brain to adapt to the damages caused by AD (Roe, Xiong, Miller, & Morris, 2007).  
An analogy often used is how the body accrues benefits to fight disease when regular 
physical exercise is performed.   
Other additional documented risk factors include chronic inflammatory 
conditions, clinical depression, strokes, high cholesterol, high blood pressure, stress, 
obesity, and toxins  (Ampuero et. al., 2008).  Though documented they have note been 
shown to be significant risk factors, but are believed to contribute to the overall chance of 
being afflicted with the disease. 
1.4 Anosognosia and Alzheimer’s disease 
The term commonly used for AD awareness deficits is anosognosia, though the 
term is also used to describe both neurological and psychological conditions.  Gabriel 
Anton first recorded a description of anosognosia in 1893 (McGlynn & Schacter, 1989).  
Gabriel reported a patient’s unwavering belief that his daughter was constantly lying by 
his left side.  The term , however, was also applied to a disorder by Babinski (1914) when 
describing the lack of awareness in two hemiplegic patients that denied their left 
hemiplegias after suffering a stroke (Feinberg et al., 2000).  
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Anosognosia as described by Babinski is directly referring to a lack of awareness of 
motor deficits, and not to any cognitive deficit within the patient (Anderson & Tranel, 
1989).  Unfortunately, the term has come to identify a variety of conditions in which the 
patient experiences a lack of awareness and this has been partially responsible for the 
many hypotheses relating to the cause of the disorder.  As previously mentioned 
anosognosia was originally associated with left-hemisphere neglect.  Currently it has also 
been used to describe the denial of symptoms in cognitive disorders and more recently it 
was used to refer to a parent, caregiver, or teacher’s inability to recognize the cognitive 
decline of children they care for (Butler & Light, 2003). 
Within the AD population, anosognosia was first used to describe the cognitive 
deficits of an individual.  Physicians have widely identified a lack of awareness among 
patient’s suffering from Alzheimer’s disease.  The most noticeable deficit is a patient’s 
ability to recognize their cognitive limitations; however, the patient may also fail to 
realize changes that occur in their behavior, as well as physical limitations they 
experience.  With these deficits in mind, investigators and clinicians have been actively 
studying the physiological, psychological, and maintenance issues of AD patients who 
present symptoms of anosognosia.  Present research has shown the number of AD 
patient’s suffering from anosognosia is approximately 20% (Migliorelli, et al., 1995), 
though the number is believed by some investigators and clinicians to be as high as 75% 
(Antoine et al., 2004).   
Anosognosia can have a direct effect on the diagnosis, intervention, treatment, 
and management of patients inflicted with the AD (Cotrell, 1997).  Important to the care 
11 
 
of the AD patient is the ability of clinicians, staff, and social workers to be able to guide 
caregivers to effective means of managing patient activities.  Giving the caregiver an 
insight into the extent of anosognosia being experienced by the patient can help to 
alleviate caregiver stress by giving them information as to why a patient may not be able 
to understand what they can and can not do.  By doing so the quality of life for the patient 
and caregiver can be enhanced.  
The diagnosis of anosognosia in hemiplegic patients is simple since it requires the 
physician only to observe a patient’s response to a number of straight forward questions 
regarding the left side of the patient’s environment (McGlynn & Schacter, 1989).  
Ramachandran and Blakeslee (1998) presented a clear example with his description of 
Mrs. Dodds, a patient who had a stroke that resulted in paralysis of her left arm.  
Whenever she was asked questions to perform an activity that required the use of her left 
arm, she would give a response that allowed her to avoid acknowledging her paralysis.  
The response would center on her unwillingness to perform a task she had already been 
asked to do, or that she was too tired to perform the task.  
 The diagnosis in the preceding case was readily made; however, the etiology of 
anosognosia is far more complex and not greatly understood (McGlynn & Schacter, 
1989).  In some cases the patient may believe they are actually performing a task 
requiring the use of a paralyzed limb, such as clapping their hands together, when in 
reality the affected limb is not responding at all.  Furthermore, there have been 
observations of patients who will altogether deny the ownership of their affected limbs, 
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claiming it belongs to someone else even though the person may not be present in the 
room or no longer alive. 
There have been a number of theories to explain anosognosia in the hemiplegic 
patient with most falling into two categories (Ramachandran and Blakeslee, 1998).  The 
first category involves the Freudian concepts of coping.  It occurs when a patient is 
unable to come to terms with their illness and they attempt to cope with the situation by 
relying on the defense mechanism of denial.  The second category takes on a neurological 
view with the denial being a direct consequence of left-hemisphere neglect.  When 
anosognosia occurs it is in relation to damage to the right hemisphere of the brain which 
supports the neurological theory. 
The cognitive deficit seen in AD patients with anosognosia involves denial of 
common AD symptoms such as memory and executive functioning impairment.  
Executive functioning consists of, but is not limited too, actions involving planning, 
decision making, error correction, or situations to resist a strong habitual response.  One 
of the earliest empirical studies on AD anosognosia was performed by Reisberg and 
colleagues (1985).  The study reported significantly less awareness of cognitive deficits 
in moderate to severe AD cases when compared to mild cases.  The investigators 
proposed that anosognosia may be the result of a defense mechanism that attempts to 
protect the individual from knowledge of their illness and thereby avoiding possible 
depression.  To explore this idea, there have been numerous attempts designed to 
examine the correlation between patient severity of AD and depression.  Feher and 
associates (1991) reported a weak negative correlation between anosognosia and 
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depression, while in a separate study by Sevush and Leve (1993) reported a significant 
negative correlation between the two. A third study by Reed and associates (1993) failed 
to find any significant correlation between depression and anosognosia in their subject 
population. 
Other investigators have moved away from searching for a psychological 
mechanism for anosognosia and instead looked at neurological damage in the frontal 
lobe.  In separate studies conducted by Lopez and associates (1994), and Michon and 
associates (1994), AD patients with anosognosia were found to have significantly greater 
cognitive deficits when compared to AD patients without anosognosia.  Both 
investigators suggested frontal lobe damage as being the cause of the anosognosia since 
the anosognosia group did worse at performing tasks related to tapping into frontal lobe 
functions.  The frontal lobes are involved in problem solving, spontaneity, memory, 
language, judgment, impulse control, and social behavior.  Damage to the region may 
cause the patient not to process fully the ramifications of actions they take.  There has 
been difficulty in replication of the studies.  The reason may be caused by many studies 
relying on a cognitive domain relating to items of memory, or spatial and temporal 
orientation, while others included a behavioral domain which includes irritability, 
selfishness, inappropriate emotional display, and lack of inhibition (Starkstein, Sabe, 
Chemerinski, Jason, & Leiguarda, 1996).   
In 1996 Starkstein and associates addressed the issue of differing domains by 
examining 186 AD patients.  The patients were administered the Anosognosia 
Questionnaire-Dementia (AD-Q) and a battery of tests geared towards determining their 
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cognitive and behavioral states.  To access behavior, subjects were given the clinical 
interview for axis 1 DSM-III-R diagnosis (SCID), the Hamilton Depression Scale (HAM-
D), Hamilton Anxiety Scale (HAM-A), Bech Mania Scale, Pathological Laughing and 
Crying Scale (PLACS), Apathy Scale, Irritability Scale, Dementia Psychosis Scale 
(DPS), and Functional Independence Measure (FIM).   To access cognitive abilities the 
Mini-Mental Status Examination (MMS), Raven’s Progressive Matrix (RPM), Wisconsin 
Card Sorting Test, Controlled Oral Word Association Test, Digit Span, Buschke 
Selective Reminding Test, Token Test, Block Design, and Similarities Test were 
administered.  The results indicated that cognitive deficits were positively correlated with 
severe intellectual decline, a higher frequency of delusions, severe apathy, and a decrease 
in depression.  Lack of awareness of behavioral changes positively correlated with lack of 
inhibition scores and severe pathological laughing.  An important finding was a very 
weak positive correlation between lack of behavioral awareness and neuropsychological 
test scores.  The authors point to these findings as further evidence to show that 
anosognosia within AD has two distinct domains with very different mechanisms. 
Concurrent studies performed with neuropsychological questionnaires on AD 
patients with anosognosia have shown significantly more deficits related to the frontal 
lobe (Lopez, Becher, Somsak, Dew, and DeKosky, 1993); (Michon, Deweer, Pillon, 
Agid, and Dubois, 1994) when compared to AD patients without anosognosia.  These 
findings suggest AD anosognosia is the result of damage to the frontal lobes, and this 
view has become readily accepted by many investigators although these studies could not 
be replicated (Bech, Kastrup, and Rafaelsen, 1986).   
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By far, the greatest problem relating to the study of anosognosia in AD patients 
stems from the heterogeneity of the population.  The progression of AD has a highly 
variable duration of disease, rate of cognitive decline, and appearance of symptoms.  
Studies designed to determine correlations between phenomena within AD and 
anosognosia often fail due to the variability found within the population.  An example of 
the problem was identified in a study performed on AD patients by Feher and associates 
(1991).  Thirty-eight AD patient were administered a battery of memory tests which 
included the Logical Memory (LM) and Paired Associate (PA) module from the 
Wechsler Memory Scale, and the Benton Visual Retention Test (BVRT).  They 
determined the level of denial by administering a standard memory questionnaire to the 
patient and caregiver.  The investigators were surprised to find only weak correlations 
between a patient’s level of denial and the severity of memory impairment. 
Reed and associates (1993), and Michon and associates (1994), reported similar 
findings when studying AD and anosognosia.  Reed and associates found the ability of 
mild and moderate AD patients to accurately report personal memory impairments had no 
direct relationship to the severity of their dementia.  Michon compared the memory of 
AD patients with mild and moderate dementia and found a high variability in self rated 
memory skills within each group.  Michon suggested that the variability was due to a 
defense mechanism caused by the patient’s depression about their illness; however, he 
quickly points out that none of the study patients were diagnosed with depression.   He 
further suggests that the amount of information an individual patient receives from 
caregivers and family may lead to a greater recognition of their deficits.  Supporting this 
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idea are studies suggesting an AD patient’s awareness of deficits may be influenced by 
the treatments they receive, the quality of available psychiatric services and social 
support, and the amount of illness related information they obtain (Johnson & Orrell, 
1995).  It has been suggested indirect interventions can help a patient to recognize the 
facets of their illness.   
Feher (1991) pointed out that AD patients have the ability to learn more complex 
insight in regards to self-awareness. Insight is retained in many AD patients without 
regard to the level of diseases severity.  Given the variability of anosognosia in the 
population, some individuals are more likely than others to benefit from awareness 
enhancing interventions.  The specific effects anosognosia is having on the patient’s 
ability to understand their personality, behavior, and cognitive abilities need to identified 
and understood before clinicians are able to determine if a patient is likely to benefit from 
an awareness intervention. 
Another difficulty with insight intervention is the possibility that a newly acquired 
insight will be bound to a specific outcome of one of the diseases symptoms (Glisky & 
Schacter, 1987).  The overall learned insight might be confused or lost if the status or 
environment of the associated symptom changes.  A patient who is helped to gain insight 
into not wandering away from the house may not maintain the behavior when moved to a 
new living location.  Butters and associates (1993) provide an opposing point of view 
stating that repetition of tasks, ideas, and concepts can cause successful learning in most 
memory-impaired patients. Their findings showed a positive correlation between 
increased repetition of tasks and the amount of learning in patients.  These authors also 
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assert that a task must be meaningful to the individual patient for successful learning to 
take place. 
Regnier and Pynoos (1992) provide guidelines to allow caregivers, working along 
with clinicians, to create an environment designed to foster insight in elderly patients 
with dementia.  In this scenario, the caregiver develops different strategies to cue 
behaviors important to everyday activities of the patient.  Examples of this strategy 
include placing the patient’s medication next to meals or making sure a comb is easily 
visible when the patient stands at the bathroom sink.  Though not a solution to all the 
problems encountered with the AD patient, the situation exemplifies the need for 
caregiver education to identify anosognosia and is important as they will be directly 
involved with the tasks necessary to try and help a patient compensate for their lack of 
awareness (Barco, Crosson, Bolesta, Werts, & Stout, 1991). 
There is still a lot to be understood about AD anosognosia.  Currently there is no 
gold standard for measuring anosognosia.  Investigators and clinicians have used 
different means to gauge anosognosia from non-validated questionnaires of their creation, 
modified versions of other scales, or basing the degree of anosognosia buy using clinician 
observation (Cotrell, 1997).  Though it is only part of the disease its can have a 
significant impact on the quality of life of the patient and caregiver.  The ability of a 
caregiver and clinician to manage the patient relies heavily on the patient being aware of 
the presenting symptoms and careful monitoring can improve the quality of life for the 
AD patient, caregiver, and family.  Necessary to accomplish this goal is easily 
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administered questionnaires capable of capturing the broad effects of the awareness 
deficit and producing results that can be easily explained to a caregiver.   
1.5 Driving, Dementia, and Alzheimer’s disease 
In 1999, there were more than 18.5 million licensed drivers over the age of 65, 
comprising 10 percent of all licensed drivers (U.S. Department of Transportation, 2000). 
This number is projected to grow to over 17 percent by the year 2020 (Marottoli, 2000). 
However, it is believed that the proportion of elderly drivers will be even greater than this 
estimate due to the increasing number of women drivers this group.  Elderly drivers 
travel fewer miles than any other age group, on average less than 2600 miles per year 
after age 80 (Dubinsky, Stein, & Lyons, 2000).  However, per mile driven, elderly drivers 
have higher rates of traffic violations, collisions, and fatalities than all age groups over 
age 25 (Beers & Berkow, 2000). 
While society recognizes the importance of maintaining the autonomy and 
independence for the elderly that are granted by driving privileges, there are inherent 
risks associated with driving that increase with age.  According to the NHTSA, in 2000, 
six percent of all people injured in traffic accidents were elderly. They made up 13 
percent of all traffic fatalities and 12 percent of all vehicle occupant fatalities.  Most 
traffic fatalities involving the elderly occurred during the daytime (81 percent), on 
weekdays (71 percent), and involved another vehicle (76 percent).  In two-vehicle 
crashes, the car driven by the elderly individual was more than three times as likely to be 
struck and more often involved maneuvers such as yielding right-of-way, heeding stop 
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signs or red lights, and negotiating intersections (U.S. Department of Transportation, 
2000); (Beers & Berkow, 2000). 
 Driving performance among older adults is affected by numerous age-related 
changes in physiology and cognition. Medical conditions and medications can affect 
vision, hearing, vehicle control, and attention. However, the single most important 
medical diagnosis affecting driving performance has been dementia, particularly AD, 
where crash rates as high as three times that of the general elderly population have been 
(Dubinsky, et al., 2000). 
Generally, in the case of medical diagnoses such as diabetes, heart failure or 
stroke, it has been found that the elderly often compensate well for their physical 
limitations and will voluntarily limit or relinquish their driving privilege (Carr, 2000). 
This has not been so with AD patients in whom the presence of anosognosia can 
adversely impact a patient’s ability to recognize poor or worsening driving performance. 
Rebok and associates (1994) stated that patients with AD tend to continue driving until an 
accident occurs or someone forcefully intervenes. Dubinsky and colleagues stated that the 
mean duration of dementia to onset of first crash was 4.0 years with an average MMSE 
score of 19.9 at the time of crash. 
Rebok provided evidence for the role of anosognosia as a contributor to high 
accident rates with the use of self-appraisal mechanisms.  These showed that while 
controls and AD patients were identical in rating their driving capabilities, the AD group 
performed significantly worse.  AD patients tended to underestimate the severity of their 
impairments and the skills necessary to avoid accidents while driving.  
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1.6 Neuroimaging and AD Related Anosognosia 
As early as 1995 research was performed using PET, MRI, and SPECT imaging 
techniques in an attempt to discover brain regions involved in the occurrence of 
anosognosia (Vogel, Hasselbalch, Gade, Ziebell, & Waldemar, 2005).  When 
investigating the ability of subjects to self-asses their cognitive and behavioral activities 
the temporoparietal junction has been reported to have high activation (Salmon, et al., 
2006); (Ruby & Decety, 2001); (Vogel & Luck, 2002).  However, during the last decade 
more studies have identified other areas of the brain with potential relationships to “self-
awareness”.  These differing results leave open the question of which areas of the brain is 
responsible for anosognosia. 
In 2005 Vogel and associates reported a decreased activity in the right inferior 
cortex using SPECT imaging techniques.  Stanonik (2002) identified other potential 
regions which included hypoactivation in the right prefrontal lobe and anterior cingulated 
cortex in subjects with anosognosia. 
The cause of these apparently conflicting results is unknown although it has been 
suggested the diverse methodology among studies may be responsible.  The various 
questionnaires being used to measure anosognosia may be the cause.  Several 
questionnaires have appeared in multiple studies, but they have not gone through 
thorough psychometric testing, while others are created specifically for a study and have 





2.1 OVERVIEW OF COLE ANOSOGNOSIA SCALE FOR ALZHEIMER’S 
DISEASE (CAS-AD) 
The development of the Cole Anosognosia Scale for Alzheimer’s disease (CAS-
AD) had two phases.  The first was the development of a 43-Item questionnaire which 
was administered to patients and caregivers.  Collected along with the 43-Item 
questionnaire were the Mini Mental State Exam (MMSE) and Geriatric Depressions 
Scale (GDS).  The two questionnaires were part of normal routine exams that every 
patient undergoes at the clinic where subjects were enrolled. 
Once sufficient data was collected (n>50) the 43-Item questionnaire was reduced 
to 10 items using Cronbach’s alpha (Cronbach, 1951) to perform item reduction.  The 
resulting questionnaire was administered to a new sample of patients along with the 
MMSE, GDS, and Clock Drawing Task (CDT-8), Trail-Making Task: Part B (TMT-B).  
The caregivers were administered the new 10-item questionnaire and the Zarit’s 
Caregiver Burden Scale (ZCBS). 
Lastly, the 10-items scale was administered to normal subjects to determine a 
cutoff score for determining individuals who had anosognosia.  The cutoff score was then 
used to identify the AD patients with anosognosia and analysis performed on their TMT-
B when compared to AD patients without anosognosia. 
The methods to analyze the data collected are described in the following sections. 
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2.2 SUBJECT SELECTION 
2.2.1 Inclusion/Exclusion Criteria for AD Subjects 
The inclusion criteria used for subjects of the 43-item and the 10-item 
questionnaire were identical.  The patient must have had a willingness to participate, 
diagnosed with AD, scored between 15 and 24 on the MMSE, and had no history of other 
dementias or any severe psychological disorders, and at least one primary caregiver with 
the willingness to participate.  A patient would be excluded from the study if all primary 
caregivers had any history of dementia or any severe psychological disorders.  All AD 
patients included in the study were current patients at the Cole Neuroscience Center, 
University of Tennessee Medical Center, Knoxville, Tennessee.  The patients completed 
all questionnaires during regular visits to the Cole Neuroscience Center Alzheimer’s 
Clinic days. 
2.2.2 Inclusion/Exclusion for Normal Subjects 
The inclusion criteria for the normal subjects were a willingness to participate, 
scored between 27 and 30 on the MMSE, no history of other dementias or any severe 
psychological disorders, and at least one caregiver willing to participate.  A subject 
would be excluded the caregiver acting as a caregiver had a history of dementia or severe 
psychological disorders.  All normal subjects included in the study were obtained from 
the Cole Neuroscience Center or Sleep Disorder Center (University of Tennessee 
Medical Center, Knoxville, Tennessee). 
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2.3 STANDARD QUESTIONNAIRES 
2.3.1 Mini Mental Status Exam (MMSE) 
The accepted gold standard in cognitive testing for dementia is the MMSE 
(Folstein, Folstein, & McHugh, 1975)).   The MMSE has a score ranging from 0 to 30 
point and tests the following categories; orientation (10 points), registration (3 points), 
attention (5 points), recall (3 points), language (8 points), and visuospatial (1 point) 
abilities.  The questionnaire must be administered by an examiner who asks a series of 
questions in a specific order.  The orientation category has 10 questions about time, date, 
and locations.  Each correct answer is scored 1 point.  Registration requires the patient to 
repeat 3 words the examiner says with 1 point scored for each (this can be done multiple 
times until the patient answers correctly, though scoring is only done on the first 
response).  Attention requires the patient to concentrate on spelling a 5 letter word 
backwards or count from 100 backwards by decrements of 7 until they reach 65.  One 
point is scored for each correct response.  Recall is tested by asking the patient to repeat 
the 3 words used in the registration part of the exam with each correct answer scoring 1 
point.  The language part is a series of 8 questions ranging from naming items to writing 
a sentence and is worth 8 points total.  Finally, the last question asks the patient to copy a 
design of overlapping figures to test visuospatial ability and is worth 1 point if the patient 
draws figures resembling the ones on the exam and they overlap appropriately. 
2.3.2 Geriatric Depression Scale (GDS) 
The GDS is a 30 item questionnaire developed to identify mild and severe 
depression in the elderly.  The questionnaire has been shown to have a strong sensitivity 
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and specificity (sensitive = 84%, specificity = 95%) (Yesavage, et al., 1982).  Each of the 
30 items is a simple sentence asking about a person’s current satisfaction with life.  The 
GDS is a self-administered questionnaire with each question being answered by circling 
“no” or “yes”.  A question has a score of 1 depending on the answer circled (“yes” is 
worth 1 with some questions and “no” in others).  The total score for the questionnaire is 
0 to 30 with 0-9 showing no depression, 10-19 mild depression, and 20-30 severe 
depression. 
2.3.3 Zarit’s Caregiver Burden Scale (ZCBS) 
The ZCBS is a widely used questionnaire measuring the level of burden felt by 
caregivers (Parks & Novielli, 2000).  The questionnaire contains 22 items which are 
answered by using a Likert scale with 5 responses.  The possible responses in order are 
“never”, “rarely”, “sometimes”, “quite frequently”, and “nearly always” with each 
answer scored from 0 to 4 respectively.  The total score ranges from 0 to 88 with a score 
between 0 and 22 indicating no burden, 23 to 44 mild burden, 45 to 66 moderate burden, 
and 67 to 88 severe burden. 
Clock Drawing: 8-Point Scoring 
• Correct Numbering (all numbers (1-12) included and no others). 
• Numbers in Correct Position 
• Numbers in Clock Circle 
• Numbers Spaced Relatively Equally Apart 
• Numbers Spaced Relatively Equal from Circle Edge 
• One Clock Hand Points to 2 
• One Clock Hand Points to 11 
• There are only 2 Clock Hands 
Fig 1. Clock Drawing: 8-Point Scoring 
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2.3.4 Clock Drawing Task: 8 Point Scoring (CDT-8) 
Clock drawing has become a standard test for visuospatial problems in 
individuals.  The patient  is asked to draw a clock with the hands pointing to 10 after 11.  
The clock drawing portion of the Self Test II (STII) (de Leonni Stanonik et al., 2005) is 
used to obtain the CDT-8.   There have  been a number of scoring methods suggested; 
however the 8-point scoring was used for the study since it has been shown to highly 
correlate with driver safety (U.S. Department of Transportation, 2000) (Fig 1).   
2.3.5 Trail Making Test – Part B (TMT-B) 
Numerous studies have been performed showing the TMT-B significantly 
correlates to driver performance and safety (Stutts, Stewart, & Martell, 1998).  The 
questionnaire is an administered test and asks an individual to draw a continuous line 
starting at the number 1 and ending with the letter L.  The line has to alternate from the 
next number in the sequence to the next letter and then again to the next number (1 to A, 
A to 2, 2 to B, etc.).  The person is corrected and helped by the administrator if mistakes 
or confusion occurs.  Not completing the test within 3 minutes indicates a higher chance 
of being in a car accident or displaying poor performance on a driving test. 
2.4 DATA COLLECTION PROCEDURES 
2.3.4 AD Subject Data Collection 
All patients and caregivers enrolled in the study were required to read and sign an 
Informed Consent approved by the University of Tennessee Graduate School of Medicine 
Institutional Review Board (IRB #2232) (Appendix C).  The questionnaires administered 
to each patient enrolled in the 43-item part of the study were the 43-Item CAS-AD, 
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MMSE, and GDS.  The caregiver was only asked to complete the caregiver version of the 
CAS-AD.  The questionnaires administered to each patient enrolled in the 10-item part of 
the study were the 10-item CAS-AD, MMSE, GDS, CDT-8, and TMT-B.  The caregiver 
also filled out the ZCBS and the caregiver version of the CAS-AD.  The MMSE, GDS, 
TMT-B, CDT-8, and ZCBS were administered as part of the patient’s normal visit to the 
Cole Neuroscience Center.  The questionnaires are routinely administered to the majority 
of the patients seen at the clinic.  The MMSE and TMT-B were required to be 
administered by staff at the Cole Neuroscience Center, while the GDS, CDT-8, and 
ZCBS did not require any supervision by staff members. All questionnaires were scored 
by the Cole Neuroscience staff or research assistants, except for the CAS-AD which was 
scored using command syntax written in SPSS v16.  The scores from the MMSE, GDS, 
ZCBS, CDT-8, and TMT-B were recorded on a top sheet and attached to the patient’s 
and caregiver’s completed CAS-AD questionnaires.  All data collected was entered into 
SPSS v16 where each subject was given a unique identifier to maintain subject privacy. 
2.4.1 Normal Subject Data Collection 
All normal subjects and caregivers enrolled in the study were required to read and 
sign an Informed Consent approved by the University of Tennessee Graduate School of 
Medicine Institutional Review Board (IRB #2232) (Appendix C).  The questionnaires 
administered to each subject enrolled in the MMSE and the 10-item CAS-AD.  The 
MMSE were required to be administered by investigators at the Cole Neuroscience 
Center and University of Tennessee Sleep Center.  All questionnaires were scored by the 








using command syntax written in SPSS v16.  All data collected was entered into SPSS 
v16 where each subject was given a unique identifier to maintain subject privacy. 
2.5 CAS-AD Development 
2.5.1 43-Item CAS-AD Development 
Two Physicians and 2 Research Associates with Masters in Experimental 
Psychology developed the initial 43-item questionnaire.  Item topics where based on the 
observations of investigators while seeing patients at the Cole Neuroscience Center’s 
Alzheimer’s clinic and adapted from a list of symptoms cited in Caring for People with 
Alzheimer's Disease: A Manual for Facility Staff  (Gwyther, 2001) (Fig. 2).  The 
symptoms listed by Gwyther have been accepted by the National Institute of Aging 
(2007).  Items created for the questionnaire were designed to reflect a broad range of 
symptoms observed throughout the course of the disease. 
The patient questionnaire had a seven page format.  The caregiver questionnaire 
had the same items as the patient form; however questions were reworded to ask about 
the patient.  Answers to items were closed ended using a 5-response Likert scale.  The 
possible responses were “Never”, “Almost Never”, “Sometimes”, “Almost Always”, and 
“Always”.  A response header was printed at the top and bottom of the page to remind 
patients and caregivers of the 5 possible responses.   
Administrators were asked to note recurring misunderstandings, confusion, or 
frustrations with items with the first 30 patients and caregivers who completed the 
questionnaire.  Those items were reviewed and modified by the investigators, and the 
questionnaire was updated to reflect any changes.  An example would be “I often wander 
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without any purpose”.  A number of patients loosely interpreted the question to mean “to 
wander about with nothing to do” so the question was reworded to “I wander aimlessly” 
which prevented any further confusion reported.  
While administering the 43-item questionnaire, administrators also uncovered a 
visuospatial problem with some AD patients not being able to correctly line up items to 
the matching response line (Fig 3).  To correct for the problem the questionnaire was 
reformatted by placing a response header over every item and separating each 
header/item with white space (Fig 4).  This made it easier for participants to line up the 
items with corresponding responses; however, it also caused the questionnaire to be 
expanded to from 4 to 7 pages. 
Once modifications were complete the questionnaire was administered to 23 new 
patients who completed the questionnaire without assistance of an administrator.  The 
first 30 patients used for the development of the questionnaire were not included in the  
 
 
Fig 3. Portion of Original 43-Item Questionnaire Layout 
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data analysis since the format of the questionnaire differed from that administered to 
patients enrolled after changes in the questionnaire format. 
2.5.2 Scoring the 43-Item CAS-AD 
The 43-Item CAS-AD was scored by assigning a value of 1 to 5 respectively to 
each item response (“Never”, “Almost Never”, “Sometimes”, “Almost Always”, and 
“Always”).  The absolute value of each patient’s item response score minus the 
caregiver’s item response score was totaled.  For the 43-Item scale the resulting score 
was divided by 43 for a result of 0 to 4. 
 
 
Fig 4. Portion of Revised 43-Item Questionnaire Layout 
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2.5.3 10-Item CAS-AD Development 
When sufficient data was collected the questionnaire’s internal reliability was 
determined using Cronbach’s-alpha and item reduction of the 43-tiem questionnaire was 
performed.   
2.5.4 Scoring for the Administration of 10-Item CAS-AD to AD Subjects 
For the 10-Item questionnaire the sum of the item scores were not divided by 10.  
This resulted in a score of 0 to 40.  The reason for using a different scoring method was 
to allow for a score consisting of integers which are easily interpretable by individuals in 
a clinic setting. 
2.6 Statistical Analysis 
All independent t-test were 2-tailed and used an alpha of 0.05.  A distribution 
would be considered normal if the skewness and kurtosis fell between the range of ±2 
(George & Mallery, 2003). 
2.6.1 Descriptive Statistics of 43-Item CAS-AD Administered to Preliminary AD 
Subjects 
Descriptive statistics were performed on the patient’s gender and age.  The 
patients were then divided into two groups by gender, and descriptive statistics for age 
were obtained, as well as skewness and kurtosis to determine if the ages of each gender 
were normally distributed.  An independent t-test was used to determine if the ages 
between genders were significantly different.  A Leven’s Test of Equality of Variance 
was used to determine if the age between genders were similar (Levene, 1960). 
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Descriptive statistics were performed on the 43-item questionnaire score for the 
total group and for each gender.  The descriptive statistics contained skewness and 
kurtosis to determine if the scores were distributed normally.  A Leven’s Test was used to 
test the Equality of Variance of scores between genders and an independent t-test was 
used to determine whether scores between genders were statistically different.   
2.6.2 43-Item CAS-AD Reduction Analysis  
Cronbach’s-alpha was used to determine the internal reliability of the 
questionnaire.  The analysis was then used to remove items from the questionnaire with 
the goal of having a 10-item questionnaire displaying Cronbach’s-alpha between 0.8 and 
0.9.  Items were removed one at a time if their removal would keep the remaining items 
Cronbach-alpha as close to 0.9 as possible.  If there were two or more items whose 
removal would result in the same Cronbach’s-alpha, the investigators removed the item 
which was perceived as the least important to the content validity of the questionnaire.  
The removal process was continued until only 10 items remained.  The resulting 10 items 
were rescored using the method described for the 43-item questionnaire and a Pearson’s 
correlation coefficient (Rodgers, & Nicewander, 1988) was obtained to determine how 
well the scores of the 43-item and 10-item questionnaire relate. 
2.6.3 Descriptive Statistics for the Administration of 10-Item CAS-AD to AD 
Subjects 
Descriptive statistics were performed on the patient’s gender and age.  The 
patients were then divided into two groups by gender, and descriptive statistics for age 
were obtained, as well as skewness and kurtosis to determine if the ages of each gender 
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were normally distributed.  An independent t-test was used to determine if the ages 
between genders were significantly different.  A Leven’s Test of Equality of Variance 
was used to determine if the age between genders were similar. 
Descriptive statistics were performed on the 10-item questionnaire score for the 
total group and for each gender.  The descriptive statistics contained skewness and 
kurtosis to determine if the scores were distributed normally.  A Leven’s Test was used to 
test the Equality of Variance of scores between genders and an independent t-test was 
used to determine whether scores between genders were statistically different.   
Reliability of the 10-item questionnaire was determined using three different 
statistical methods. A Cronbach’s-alpha was performed to determine the internal 
reliability of the questionnaire.  A Pearson’s-r correlation coefficient was used to 
determine test-retest reliability of the questionnaire and a One-way Intraclass Coefficient 
(ICC) (Koch, 1982) was used to determine inter-rater agreement.   A split-half reliability 
analysis was use to obtain a spearman-brown coefficient for equal length parts (Brown, 
1910); (Spearman, 1910). 
Descriptive statistics for the MMSE, GDS, CDT-8, TMT-B, and ZCBS were 
determined for the patient population and the population divided by gender.  A Pearson’s-
r was used to determine if significant correlations exist between afore mentioned 
questionnaires and the 10-item questionnaire score for the patient population total and by 
gender.  A 2-tailed independent t-test was performed for each questionnaire to determine 
if any significant difference existed between genders. 
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2.6.4 Descriptive Statistics for the Administration of 10-Item Questionnaire to 
Normal Subjects 
The statistical process used in section 2.6.1 was used to analyze the group of 
normal subjects enrolled for the 10-item administration of the questionnaire.  A 2-tail 
independent t-test was performed for ages between the AD patients and normals who 
took the 10-Item questionnaire to make sure the groups were of similar age (de Leonni 
Stanonik, et al., 2005). 
2.6.5 Analysis of AD Subjects with and without anosognosia based on Administered 
10-item CAS-AD 
A cutoff score for the 10-Item CAS-AD was determined to define anosognosia 
among AD patients.  The cutoff score was calculated as 2 SD above the mean of the 
normal population.  The 10-item AD group was divided into two groups; those without 
and with anosognosia.  A one-tail independent t-test was performed to determine if any 






3.1 Descriptive Statistics of 43-Item CAS-AD Administered to Preliminary AD 
Subjects 
One-hundred and six Alzheimer patients who met the inclusion criteria were 
enrolled in the study.  Thirty-nine were excluded due to incomplete questionnaires with 
the final number being 67 (age: u = 72.66, SD = 3.40), with 41 females (age: u = 72.39, 
SD = 4.58) and 26 males (age: u = 73.08, SD = 4.14).  The age between genders showed 
no significant difference existing (t(65) = 0.537, p = 0.593) (Table 4). 
The 43-Item Questionnaire score for the population had a mean of 0.87 (SD = 
0.42) with the mean score for females being .87 (SD = 0.42) and males .87 (SD = 0.36).  
Since the kurtosis of the scores for females was 2.68 (female: median = 0.76, range =  




Table 5. 43-Item Subjects Statistics with 10-Item Scoring 
 
 
Table 6. 10-Items After Item Reduction 
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2.10; male: median = 0.81, range = 1.36) the scores were transformed using log10 to 
create a normal distribution.  The females mean was -0.10 (SD = 0.20) and males -0.10 
(SD = 0.18).  Using the transformed scores between genders equal no significant 
difference was found (t(65) = 0.142, p = 0.887). 
3.2 43-Item CAS-AD Reduction Analysis 
The 43-item questionnaire had a Cronbach's-alpha of 0.89 was obtained showing 
the questionnaire had excellent internal reliability.  The 10-Items left after reduction were 
scored using the sum of item scores divided by 10.  The mean score was 1.10 (SD = 0.63) 
with the mean score for females being 1.13 (SD = 0.64) and males 1.05 (SD =0.63).  The 
10-item scores between genders showed no significant difference (t(65) = -0.498, p = 
0.620) (Table 5).  The reduction of the questionnaire to 10-items produced a Cronbach’s-
alpha of 0.84 (Table 6).  A significantly high correlation (r =0.90, p < 0.000) was found 
when the final 10 items identified were rescored and compared to the original 43-item 
questionnaire scores.   
3.3 The Administration of 10-Item CAS-AD to AD Subjects 
Of the eighty-four new AD patients enrolled in the second phase of the study 
using the 10-item questionnaire; one patient dropped out citing privacy concerns (Table 
7).  The total number of patients used was 83 (age: u = 75.53, SD = 3.83), with 58 
females (age: u = 75.21, SD = 3.80) and 25 males (age: u = 76.28, SD = 3.89).  The 
patients age between genders showed no significant (t(81) = -1.176, p = 0.243).  The 
mean 10-item score was 12.94 (SD = 6.94), with females mean score of 12.81 (SD =  
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 7.21) and males 13.24 (SD = 6.39).  The scores between genders showed no significant 
difference (t(81) = -0.257, p = 0.798). 
Internal reliability of the new questionnaire remained high with an obtained 
Cronbach’s-alpha of 0.87 (Table 6).  Nineteen of the 83 patients who each had 2 
caregivers acting as informants were used to determine the inter-rater agreement. The 
ICC single measure alpha was 0.63 (p < 0.000).   Twenty-one of the 83 patients were 
used to evaluate the test-retest over time using scores from initial enrollment and 3 month 
follow up visit. Results showed a significantly high correlation (r = 0.70, p < 0.000).  
Using the 83 patients split-half reliability was found to be significantly high (n = 83, r = 
0.86, p < 0.000). 
For the patient population the mean for the MMSE (u = 21.30, SD = 2.59), GDS 
(u =6.29, SD = 4.93), CDT-8 (u = 5.12, SD = 2.58), and ZCBS (u = 29.37, SD = 17.36) 
Mean scores for the questionnaires were obtained for females (MMSE: u = 21.10, SD = 
2.75; GDS: u = 6.41, SD = 5.29; CDT-8: u = 4.83, SD = 3.32; ZCBS: u = 28.12, SD = 
16.61), and males (MMSE: u = 21.76, SD = 2.17; GDS: u = 6.00, SD = 4.03; CDT-8: u 
= 32.28, SD = 3.81; ZCBS: u = 5.80, SD = 2.63).  
A significant differences was not found among male and female study patients for 
any of the questionnaires (MMSE: t(81) = -1.06, p = 0.292; GDS: t(81) = 0.35, p > 
0.728; CDT-8: t(81) = -1.00, p > 0.320; ZCBS: t(81) = -1.59,  p > 0.116).  Correlations 
between the sample population 10-item questionnaire score and the MMSE (r = -0.24, p 
= 0.032), and GDS (r = -0.30, p = 0.006) were significant though weak, where the  
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correlation with the CDT-8 (r = -0.04, p = 0.743), and ZCBS (r = 0.04, p = 0.699) 
showed no significance (Table 7).   
3.4 Descriptive Statistics for the Administration of 10-Item CAS-AD to Normal 
Subjects 
There were 43 normal subjects enrolled in the study (age: u = 73.95, SD = 3.90) with 23 
females (age: u = 73.83, SD = 4.23) and 20 males (u = 74.10, SD = 3.60).  Age between 
genders showed no significant difference (t(41) = 0.227, p = 0.822) (Table 8).  The mean 
MMSE score for the sample population was 29.67 (SD = 0.75).  The distribution does not 
have a normal curve, however this is expected since the MMSE scores of the normal 
population are expected to not have adequate variance.  The age between the AD Patients 
administered the 10-item questionnaire and normal subjects showed no significant  





Table 8. Normal Subject Statistics 
 




difference in age.  The ages between groups had unequal variance (F = 15.330, p < 
0.000), with the t-test result for unequal variance showing significant difference in age 
between groups (t(123.68) = 1.778, p = 0.078).  The mean CAS-AD score for the normal 
subjects was 7.19 (SD = 2.22) with females having a mean of 7.26 (SD = 2.24) and males 
7.10 (SD = 2.25).  No significant difference in scores was found when comparing 
between gender (t(41) = -0.235, p = 0.816).   
3.5 Analysis of AD Subjects with and without anosognosia based on Administered 
10-item CAS-AD 
Using the mean and SD of the normal subjects a cutoff score to define anosognosia was 
determined to be 12.  There were 41 (49%) patients who did not fit the definition for 
anosognosia (age: u = 74.23, SD = 8.05) and 42 (51%) with anosognosia (age: u = 77.41, 
SD = 7.73).  The age between the groups with and without anosognosia showed no 
significant difference (t(81) = -1.839, p = 0.070) (Table 9). 
For patients without anosognosia the mean score for the MMSE was 21.46 (SD = 
2.51), GDS was 7.54 (SD = 7.54), ZCBS was 28.95 (SD = 18.01), and CDT-8 was 5.00 
(SD = 2.48).  For patients with anosognosia the mean score for the MMSE was 21.14 (SD 
= 2.68), GDS was 5.12 (SD = 3.78), ZCBS was 31.12 (SD = 17.26), and CDT-8 was 5.19 
(SD = 2.70). 
 Unequal variance was found between patient groups with and without anosognosia for 
GDS scores (F = 7.657, p = 0.007).  Patients without anosognosia had a significantly 
greater GDS score then patients without anosognosia (t(69.24) = 2.273, p = 0.026).  The  
 MMSE ((t(81) = 0.562, p = 0.576), ZCBS ((t(81) = -0.560, p =.577), and CDT-8 ((t(81)  
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= -0.335, p = 0.738) showed no significant differences in mean scores between patients 
with and without anosognosia. 
There were 22 patients willing to complete the TMT-B, ten of which did not meet 
the criteria for anosognosia (Table 10).  Ten were without anosognosia (age: u = 74.00, 
SD = 6.37) and 12 with (age: u = 77.33, SD = 8.55).  Age between patients with and 
without anosognosia showed no significant difference (t(20) = -1.018, p = 0.321).  The 
mean scores for the TMT-B for patients without anosognosia was 16.67 (SD = 5.55) and 
with was 14.70 (SD = 5.95) with no significant difference existing (t(20) = -0.802, p = 
0.432).   




4.1 43-Item CAS-AD 
The CAS-AD was begun in 2001 as a companion questionnaire for an fMRI 
imaging investigation into the possible role the anterior cingulate cortex (ACC) plays in 
the area of attention and self awareness (Stanonik, 2002).  The study consisted of normal 
controls and AD patients.  The AD patients were further divided into with and without 
anosognosia groups using the 43-Item CAS-AD with a cutoff point of 1.   Anosognosia 
was used as a means of distinguishing subjects who had a deficit of self awareness and 
the MRI images obtained were analyzed to determine if the ACC activation was 
significantly different in the Anosognosia subject when compared to the other groups (the 
study found a significant hypoactivation in the anosognosia group).   
At the time of the 2001 study a questionnaire called the Anosognosia 
Questionnaire for Dementia (AD-Q) (Migliorelli et al., 1995) was going to be used which 
had been developed for an fMRI study performed in Argentina.  After reviewing the 
material there was concern with problems in translation of the questions since every item 
was preceded with the negative sounding phrase “Do you have problems”.  This concern 
prompted the investigators to administer the questionnaire to several patients to evaluate 
how individual’s felt about the questions. It was concluded by the investigators that the 
patients were feeling potential levels of anxiety due to the questionnaire’s wording and it 
was the desire of the investigators to minimize as much stress as possible.  The 
investigators decided not to use the AD-Q and instead create a questionnaire for use in 
the study with specific care taken to make it as minimally evasive as possible. 
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4.2 Subject Selection for 43-Item and 10-Item CAS-AD 
The inclusion and exclusion criteria for the study were a carry over of the original 
2001 fMRI study.  Due to the nature of the study, the criteria were more rigid than 
necessary for the psychometric testing and should have been changed in order to include 
a more culturally diverse group of subjects.  The removal of the MMSE score 
requirements and whether the patient had past psychological disorders would have 
allowed for the study to be generalized to a larger AD population and increase the 
statistical power of the study, though it would have added numerous confounding 
variables. 
Another limiting factor to the number of individuals included in the study was the 
active clinic setting where the data was collected.  Data collection occurred during patient 
visits to the office which limited the time available to administer questionnaires not 
specific to a patient’s visit.  The Cole Neuroscience Center does not have a diverse socio-
economic or minority population.  The current study’s population exclusively contained 
Caucasians.  Both of these factors put into question the validity of the questionnaire in the 
general population, though the simplicity of the questionnaire’s items should allow it to 
span across ethnic groups and education levels. 
4.3 43-Item CAS-AD 
The items used were meant to capture a broad spectrum of symptoms seen 
throughout the 3 stages of the AD Mild, Moderate, and Severe.  The item creation 
method used could bring into question the face validity of the questionnaire.  Another 
method would have been to poll the caregiver population to determine common recurring 
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symptoms and concerns (Streiner & Norman, 1995).  To perform data collection in the 
following manner would have required additional time which was not conducive to the 
time constraints of the initial ACC study.  Nevertheless, the items came from reliable 
sources and are believed to have adequately reflected common caregiver observations.  In 
order to show internal reliability a Cronbach's-alpha between 0.8 and 0.9 is desired 
(George & Mallery, 2003).  The internal reliability of the questionnaire was high (r = 
0.89) showing a significant degree of association between the items.   
Though the 43-Item questionnaire could be used on its own, it was the intention 
of the investigators to create a more accessible 10-Item scale for both research and 
clinical settings.  The significantly strong correlation (r = 0.90) between the 43-tiem and 
10-item version of the instrument demonstrates the shorter version is as reliable as its 
longer version.  This allows the shorter version to be ideal for setting where it is 
important for a questionnaire to be administered in a timely manner. 
4.4 10-Item CAS-AD 
After being administered to a new sample AD patients the internal reliability of 
the 10-Item questionnaire remained high (cronbach’s-alpha = 0.87) showing the items 
related well to each other while maintaining adequate variability.  The questionnaire 
allows for anosognosia to be measured in two different ways.  First, the score can be used 
as a measurement of the degree of anosognosia on a continuum.  Second, the 
questionnaire can be used to diagnose anosognosia in the AD patient by using the cutoff 
score of 12.     
As expected, when using the entire sample population there was a statistically 
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significant, but small correlations found between the total 10-Item CAS-AD and the 
MMSE (r = -0.24, p < 0.05) or GDS (r = -0.30, p < 0.05).  Though some prior research 
has shown anosognosia to have a high correlation with cognitive decline and depression 
(but not necessarily with both together)( Sevush & Leve, 1993), it is believed that 
anosognosia is its own unique phenomena which is not related to degree of dementia or 
depression ((Feher, Mahurin, Inbody, Crook, & Pirozzolo, 1991);  (Reed, Jagust, & 
Coulter, 1993).  The low correlation adds credence to this hypothesis. 
To asses the stress associated with caregivers a correlation of the ZCBS was 
performed using the 10-Item questionnaire AD population with no significant correlation 
being found (r = -0.04, p = 0.699).  The opposite results were expected with caregiver 
stress increasing as the severity of anosognosia increased.  It is expected that the results 
may be a function of the inclusion criteria using the MMSE score.  Excluded from the 
study were patients with more severe dementia.  It is hypothesized caregivers of subjects 
with more pronounced dementia may increase the mean of the stress for the group with 
anosognosia and a significant difference would be found.  Furthermore, it uncertain if the 
high level of social work intervention provided at Cole Neuroscience Center may be 
adding a confounding variable in regard to caregiver stress. 
4.5 Inter-rater and Test-retest Reliability of 10-Item CAS-AD 
The resulting ICC for the questionnaire was high (r = 0.63, p < 0.05), but a result 
greater then 0.70 is desired.  Though not as high as hoped for it is considered to be 
satisfactory given the nature of the caregivers which are being used in the study.  AD 
patients who attended the clinic with more then one caregiver would have a spouse and a 
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child with them.  The varying contact the caregivers might have with the patient is a 
confounding factor which could have caused a discrepancy, there by lowering the ICC 
result. 
Results of  test-retest analysis among patients yielded a  Pearson-r correlation of 
0.70 (p < 0.000).  Like the ICC, this is not as high as would be desired, but good enough 
to be able to say with confidence that the questionnaire was reliable when administered 
over time.  The target period used was 3 months; however one of the factors which could 
not be accounted for was the use of pharmaceutical medication during the test-retest 
period which may increase or maintain a patient’s cognitive ability.  Though denying 
drug therapy would be the best way to perform test-retest reliability, it would be unethical 
to deny treatment.  
4.5 AD Subjects with and without anosognosia as Diagnosed by 10-Item CAS-AD 
There was no significant difference in age between the AD subjects and normals 
who took the 10-Item questionnaire (t(123.68) = 1.78, p > 0.05) which increases the 
confidence that the normal group appropriately reflected the ages of AD group and 
allowed for the setting of the cutoff score based on the normals mean and SD (de Leonni 
Stanonik, et al., 2005). 
Fifty-one percent of the AD subjects had anosognosia (n = 42) when using the 
cutoff score of 12.  The prevalence of anosognosia among study patients is approximately 
midway between the reported numbers of 20% to 75% (Migliorelli, et al., 1995); 
(Antoine, Antoine, Guermonprez, & Frigard, 2004) 
Depression scores between AD subjects with and without anosognosia showed 
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that subjects with anosognosia had a significantly lower level of depression (t(69.24) = 
2.27, p < 0.05).  The result was unexpected, but it does show that anosognosia may have 
a  relationship with the levels of patient depression, stressing the importance of the low, 
but significant correlation between depression scores and the 10-item score of the 83 AD 
subjects. 
Driving 
Driving is one of the activities essential to the independent life style of most 
individuals today.  There is a noticeable decrease in driving skill as people age and the 
effects are worsened with the advent of dementia (U.S. Department of Transportation, 
2000).  Even though in mild AD patients there is still an ability to control vehicles, they 
are at increased risk of getting lost, making incorrect turns, and causing at-fault errors on 
driving simulation tasks (Uc, Rizzo, Anderson, Shi, & Dawson, 2004). 
It is important in the management of an AD patient to limit, or even better, cease 
driving.  Since driving is so empowering to an individual’s sense of independence it often 
becomes difficult to get compliance (Steven W Anderson, Rizzo, Shi, Uc, & Dawson, 
2005).  Research by Freund and associates (2005) showed elderly drivers without 
dementia who considered themselves better than other drivers their age were over four 
times more likely to be unsafe drivers when compared to those who rate themselves as 
being comparable to or worse than other drivers of their age.  Freund specifically points 
out the problem in determining why the unsafe drivers may over rate their abilities.  
Though a lack of awareness was mentioned the study was not designed to determine 
anosognosia was a factor.  Nevertheless, even though the subjects of the study did not 
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have AD or other dementias, it still manages to underscore the importance of AD patients 
ceasing driving activities. 
Important for caregivers to understand is anosognosia does not relieve the patient 
or their estate of legal liability in the event of a driving accident.  In every state public 
policy forces persons with disabilities to pay for damage they do if they “are to live in the 
world.”  The policy clearly indicates how a lack of awareness of driving ability does not 
break the chain of causation in a liability suite, thereby causing eliminating anosognosia 
as a valid defense. 
The CDT-8 and TMT-B are used to measure driver safety with low scores in both 
indicating decreased driver ability.  Using the entire study sample, the CDT-8 showed no 
slightly negative, non-significant correlation to the anosognosia scores (r = -0.04, p > 
0.05).    The t-tests comparing AD subjects with and without anosognosia on the TMT-B 
produced no significant results (t(20) = 0.43, p > 0.05), though the sample size used for 
the test was relatively small (with anosognosia: n = 10, u = 14.70, SD = 5.945; without 
anosognosia: n = 12, u = 16.67, SD = 5.549). 
The low negative correlation with the MMSE and the 10-item questionnaire 
scores administered to AD patients might mean anosognosia occurs independently of 
cognitive decline which would make the CDT-8 and TMT-B results expected.  Further 
research would need to be performed with more sensitive testing, such as a driving 
simulator.  Though the questionnaire could not be used to make any definitive statement 
about an AD patient’s ability to drive the results would still be beneficial for a clinician to 





Though anosognosia can be viewed as existing on a continuum it was shown 
through the use of normal subjects that a cutoff value could be identified.  This allows for 
the scoring of the questionnaire to accurately diagnose a patient as having anosognosia. 
The study lacked sufficient sample sizes to come to definitive conclusions about 
the reliability of the questionnaire.  Yet the lack of or significantly low correlations of the 
10-item questionnaire scores for the patients (n = 83) with the other questionnaires 
administered shows the questionnaire is measuring a separate and unique factor 
associated with AD.  Further investigation should include a larger sample size, have 
greater control over collecting return data and include a greater number of patients with 
multiple caregivers.  In addition, the inclusion/exclusion criteria should be relaxed, 
allowing for a sample population reflective of most of the population seen at clinics.  A 
comparison of the 43-Item and 10-Item questionnaire would be of interest to determine if 
questionnaire format has any effect on score outcomes. 
The CAS-AD questionnaire is unique since it was designed specifically for the 
study of patients with AD and not all dementias. It has gone through more rigorous 
psychometric testing then previous questionnaires.  In the past, investigators have 
developed questionnaires based on the need of an ongoing study and no attempt has been 
made to assess the reliability or validity of the questionnaire.  This situation has resulted 
in numerous studies that can not be easily compared to one another since it is uncertain if 
they are measuring the same phenomena.  The 10-Item CAS-AD offers investigators a 
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more accurate way to study AD related anosognosia by using a single reliable 
questionnaire for diagnosis.  The value of the questionnaire within the clinic comes from 
its ease of administration and the assistance it can give to physicians and social workers 
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